Spinal Muscular Atrophy Trial, Recruiting NCT05866419 Sponsor: Alcyone Therapeutics, Inc Condition: Spinal Muscular Atrophy
Back to Spinal Muscular Atrophy

Spinal Muscular Atrophy Trial, Recruiting

NCT05866419
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 3 years old or older
  • You have been diagnosed with Spinal Muscular Atrophy (SMA) and are a candidate for a drug called Spinraza (nusinersen)
  • You have difficulty receiving spinal injections (lumbar punctures) safely — either because breathing problems or other health conditions make repeated anesthesia and X-ray exposure risky, or because your doctor believes the device being studied is otherwise in your best interest
  • Your doctor has prescribed Spinraza to be delivered through a special implanted port system, and the first use of that port is planned within 2 weeks of the device being put in
  • Your doctor determines you are able to have a surgical procedure (either minimally invasive or open surgery) to implant the port and catheter, with at least a small length of tubing placed in the spinal fluid space
  • You (or your legal guardian) are willing and able to give written consent to participate
  • You and your parent or caregiver are able and willing to attend all required study visits and complete all study procedures

Who may not be able to join:

  • You have any health conditions that make the ThecaFlex DRx™ device unsafe for you to use (confirm with trial site)
  • You have had, or currently have (within the last 6 months), another implanted drug delivery device, spinal catheter, fluid drainage shunt, or reservoir in the spinal fluid space
  • You are pregnant, breastfeeding, or planning to become pregnant during the study
  • You have severe physical characteristics that would make it unsafe to implant the catheter or port
  • You have had a major medical event within the last 60 days
  • You have had surgery involving the head, neck, or back within the last 60 days, or have such surgery planned during the study period
  • You have certain structural brain or spine conditions, such as a mass pressing on brain or spinal tissue, a growth at the base of the skull, or a condition called Arnold-Chiari malformation (confirm with trial site)
  • You have problems with blood clotting or low platelet levels
  • You do not have enough skin or body tissue to safely cover and protect the implanted port
  • You have a medical reason why you cannot receive Spinraza
  • You have a history of a type of tissue growth (granuloma) forming around spinal catheters
  • You have had a spinal fluid infection (bacterial or aseptic meningitis) within the last 6 months
  • You have a history of tumors or other spinal abnormalities that would interfere with the catheter placement or spinal fluid flow
  • You have a history of a condition causing fluid build-up in the brain (hydrocephalus)
  • You have been diagnosed with another muscle-wasting disease in addition to SMA
  • You have a history of depression, significant memory or thinking problems, or behavioural issues that your doctor believes could make participation unsafe
  • Your doctor believes your current medical condition may mean a life expectancy of less than 12 months
  • You are currently taking part in another medical device research study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 857-500-7526

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Alcyone Therapeutics, Inc
Registry
ClinicalTrials.gov
Start date
27 November 2023
Est. completion
1 April 2028

Where this trial is recruiting

🇩🇪 Germany 🇵🇱 Poland 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

The proportion of subjects with successful Implantation of the ThecaFlex DRx™ Port and Catheter; The proportion of subjects with successful Intrathecal Therapy Infusion(s) through 12 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov